ESR1 and breast carcinoma: HR+ breast cancers have the best prognosis and can be treated with tamoxifen, an ER antagonist, fulvestrant, which directly hampers ER synthesis, and aromatase inhibitors, namely, anastrozole, exemestane, and letrozole [47].